pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
296
stories
Jul 7, 26
Kailera says obesity pill succeeds in late-stage trial in China
biopharma dive
Jul 1, 26
Merck scraps a Phase 2 Alzheimer's asset from partner Neuphoria
endpoints
Jul 1, 26
Abivax shares surge as worries subside over immune drug’s cancer risk
biopharma dive
Jun 30, 26
These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
biopharma dive
Jun 30, 26
Beeline ups its Series A round for immune drug work
biopharma dive
Jun 29, 26
FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing
fda press
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 26, 26
FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services
biopharma dive
Jun 18, 26
cAMPfield lands $180M to build gut disease drug
biopharma dive
Jun 18, 26
Pfizer CFO to step down; Denali sells a regulatory fast-pass
biopharma dive
Jun 18, 26
STAT+: Pharmalittle: We’re reading about an FDA review of Moderna’s flu shot, J&J’s focus on cancer, and more
stat
Jun 18, 26
Innoviva revives Lyndra's long-acting oral drug platform
endpoints
Jun 16, 26
STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
stat
Jun 12, 26
FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children
fda press
Jun 11, 26
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
biopharma dive
Jun 11, 26
Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3
endpoints
Jun 11, 26
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
biopharma dive
Jun 9, 26
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
biopharma dive
Jun 9, 26
Gilead and Merck’s latest trial success and flop
stat
Jun 9, 26
Alcohol study discarded by Trump officials is published in scientific journal
stat
Jun 8, 26
STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
stat
Jun 8, 26
City banks nearly $100M for next-gen RNAi drugs
biopharma dive
Jun 8, 26
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
biopharma dive
Jun 3, 26
STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and more
stat
Jun 2, 26
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
biopharma dive
Jun 1, 26
RallyBio tries again for reverse merger, this time with Avenzo
biopharma dive
Jun 1, 26
Shionogi wins US approval for first pill to prevent Covid following exposure
endpoints
Jun 1, 26
STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
stat
May 31, 26
Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
stat
May 29, 26
Opinion: I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
stat
← prev
page 6 of 10
next →
